Sensei biotherapeutics presents trial-in-progress poster for phase 1/2 clinical study of sns-101 at esmo 2023

Boston, oct. 23, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented a trial-in-progress poster from the phase 1/2 clinical trial for sns-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint vista (v-domain ig suppressor of t cell activation), at the european society for medical oncology congress (esmo) 2023.
SNSE Ratings Summary
SNSE Quant Ranking